INTRODUCTION
There are, today, no curative therapies for locally advanced or recurrent metastatic prostate cancer and novel treatment options are urgently needed. Immunotherapy with the aim to activate tumor-associated antigen (TAA)-reactive T cells is particularly well suited for prostate cancer. An important reason is that a large number of proteins with specific or preferential expression in normal prostate and prostate cancer cells have been identified [1] . Since the prostate gland is an organ that one can live without, these proteins constitute suitable targets for T cell-based immunotherapy. Immune responses to prostate-related antigens can be considered tumor-specific in patients with recurrent metastases after radical prostatectomy. Furthermore, serum prostate specific antigen (PSA) can be used as a surrogate marker to evaluate clinical responses. Breast cancer share many features with prostate cancer and strategies for prostate cancer immunotherapy can in many cases be applied also for breast cancer. For example, PSA and other kallikreins that are expressed by prostate cancer cells are also found in breast cancer cells [2, 3] .
The major cell type that mediates the rejection of solid tumors in preclinical animal models is the cytotoxic T lymphocyte (CTL). CTLs recognize 9-11 amino acid long peptide fragments bound to major histocompatibility complex (MHC) class I molecules, also known as human leukocyte antigen (HLA)-ABC, on the surface of the antigen presenting cell or target cell. Successful experimental cancer immunotherapy requires representative cell lines that can be used as target cells to verify the efficacy of activated CTLs. It is therefore of particular interest to know the HLA-ABC genotype and HLA-ABC expression level of the target cell lines. Cancer cell lines can also be used as antigen presenting cells for T cell activation, that is, as cancer vaccines. It is then of importance to know the expression levels of costimulatory molecules such as B7.1 (CD80), B7.2 (CD86), and CD40 as well as adhesion molecules such as ICAM-1 (CD54) since these molecules highly influence the quality of T cell activation. Furthermore, it is of outmost importance to know whether the laboratory cell lines express TAAs found in clinical cancer. Many of these characteristics have not yet been established and we therefore set out to sequence the HLA-A and HLA-B loci of six commonly used prostate cancer and immortalized normal prostate epithelial cell lines and two breast cancer cell lines. We also analyzed their surface expression of HLA-ABC (MHC class I), HLA-DR (MHC class II), CD40, CD80, CD86, and CD54 and investigated how the expression is influenced by exposure to interferon gamma (IFN-g). In addition, we have analyzed the cell lines for mRNA expression of a large number of genes reported to be specifically or preferentially expressed by normal prostate and prostate cancer cells.
MATERIALS AND METHODS

Cell Lines
The human prostate adenocarcinoma cell lines LNCaP [4] , PC-3 [5] and DU145 [6] , and the immortalized normal human prostate epithelial cell lines BPH-1 [7] were obtained from ATCC (Rockville, MD). The prostate adenocarcinoma cell line PC-346C [8] was obtained from Dr. C Bangma, Erasmus University, Rotterdam, The Netherlands. The immortalized normal human prostate epithelial cell lines PNT2-C2 [9] and the human breast carcinoma cell line T47D [10] were obtained from Dr. N Maitland, York University, York, UK. The human breast carcinoma cell line MCF-7 [11] was obtained from Dr. J Berg, Karolinska Institute, Stockholm, Sweden. LNCaP, PC-346C, PC-3, DU145, BPH-1, PNT2-C2, and MCF-7 were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES and 1 mM sodium pyruvate while T47D was cultured in DMEM supplemented with 5% FBS and 2 mM L-glutamine. All cell culture reagents were from Invitrogen (Carlsbad, CA).
Sequencing of the HLA-A and HLA-B Loci
The HLA-A and HLA-B loci of the immortalized prostate, prostate cancer, and breast cancer cell lines were sequenced using previously described methods [12] .
Flow Cytometry Analysis
Prostate and breast cancer cell lines were analyzed by flow cytometry (FACSCalibur TM , BD Biosciences, San Jose, CA) using the following antibodies: FITClabeled anti-HLA-ABC (BD Biosciences), FITC-labeled anti-HLA-A2/A28 (One Lambda, Canoga Park, CA), PE-labeled anti-HLA-DR (BD Biosciences), FITClabeled anti-CD40 (BD Biosciences), PE-labeled anti-CD80 (BD Biosciences), APC-labeled anti-CD86 (BD Biosciences), and APC-labeled anti-CD54 (BD Biosciences). A fraction of cells were pretreated with 1,000 IU/ml IFN-g (Imukin TM , Boehringer-Ingelheim, Ingelheim, Germany) for 72 hr. Unspecific antibody bindings were analyzed by staining with isotypematch FITC-, APC-, and PE-labeled control antibodies (BD Biosciences).
Reverse-Transcription (RT)-PCR
To evaluate expression of 25 prostate-associated antigens, total RNA was isolated from all cell lines using TRIzol (Invitrogen) and cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Five micrograms of total RNA were used for each cDNA synthesis and an oligo-dT primer and a random hexamer primer were used in parallel reactions. Onetenth of the cDNA obtained from the oligo-dT cDNA synthesis and one-tenth of the cDNA obtained from the random hexamer cDNA synthesis were pooled and used as template for 35 cycles of PCR using the Expand TM polymerase enzyme mix (Roche, Mannheim, Germany). In order to amplify cDNA only and not trace amounts of genomic DNA the primer pairs for each transcript were designed to generate PCR products spanning at least two exons. The primer sequences, annealing temperatures, and expected PCR product sizes are shown in Table I . PCR products were visualized by ethidium bromide staining on 2% agarose gels. many cases the full HLA genotypes of the cell lines are not known. We sequenced the HLA-A and HLA-B loci in four prostate cancer cell lines (LNCaP, PC-346C, PC-3, and DU145), two immortalized normal prostate epithelial cell lines (BPH-1 and PNT2-C2) and two breast cancer cell lines (MCF-7 and T47D). The results are presented in Table II . HLA-A*0201 is the most commonly targeted human MHC class I molecule in T cell-based immunotherapy. Of the cell lines sequenced herein, LNCaP, PC-346C, and MCF-7 have an HLA-A*0201 genotype.
Cell Surface Expression of Immune Cell Interacting Molecules
The expression level of MHC class I molecules (HLA-ABC) on the surface of target cells is crucial for CTL-mediated cell lysis. Therefore, we analyzed the expression level of HLA-ABC and HLA-A2 by flow cytometry on the panel of cell lines. The results are presented in Figure 1 . We observed that the HLA-ABC expression varied substantially among cell lines with LNCaP and PC-346C displaying the lowest and PC-3 the highest HLA-ABC expression, Figure 1A . We also found that the HLA-ABC expression on LNCaP and PC-346C was not effected by IFN-g stimulation while PC-3, DU145, BPH-1, PNT2-C2, MCF-7, and T47D substantially upregulated HLA-ABC cell surface expression upon IFN-g stimulation. The HLA-A2 expression correlated well with the overall HLA-ABC expression on the HLA-A*0201 positive cell lines, Figure 1B .
The expression levels of costimulatory molecules and adhesion molecules are important for T cell activation and to some extent for CTL-mediated target cell lysis. We therefore analyzed the cell surface expression of CD40, CD80, CD86, and CD54 as well as HLA-DR by flow cytometry on the panel of cell lines. The results are presented in Table III . The expression of the costimulatory molecules CD40, CD80 and CD86
The Prostate DOI 10.1002/pros were non-existing or very low for all cell lines and IFNg treatment did not change this fact. The adhesion molecule CD54, on the other hand, was relatively highly expressed by all cell lines except for LNCaP and PC-346C. IFN-g treatment marginally increased the expression on CD54-positive cell lines except for BPH-1 where IFN-g treatment dramatically decreased CD54 expression. HLA-DR expression was relatively low but efficiently upregulated by IFN-g in all cell lines with the exception of LNCaP and PC-346C.
Prostate Antigen mRNA Expression in Prostate and Breast Cancer Cell Lines
For experimental immunotherapy it is important to have appropriate cell lines that express prostate antigens and present peptide epitopes derived from these antigens. We therefore set out to examine the expression of prostate-related genes in the panel of cell lines. RT-PCR analyses were preformed to determine mRNA expression of 25 genes reported to be specifically or preferentially expressed by normal and malignant prostate cells. The result of the screening is presented in Table IV . LNCaP expressed all examined genes while PC-346C expressed all genes except PSGR and NGEP. It is noteworthy that PSA expression is lost in the prostate cell lines PC-3, DU145, BPH-1, and PNT2-C2. The breast cancer cell line MCF-7 expressed 16 out of 25 genes while T47D expressed 8 out of 25 genes. STAMP1, Cten, AIbZIP, and PSDR1 were the only genes expressed by all examined cell lines.
DISCUSSION
In order to develop experimental immunotherapy for prostate cancer and breast cancer it is of outmost importance to have representative target cell lines that present relevant levels of peptides from TAAs on HLA class I molecules. Since HLA-A*0201 is the most common HLA class I molecule in humans, most studies describing the generation of T cells against prostate TAAs have focused on HLA-A*0201-restricted peptides [1] . Furthermore, most studies have used LNCaP as target cells despite the fact that LNCaP has an intracellular defect in the assembly of the MHC class I molecule [13] [14] [15] . In order to expand our knowledge of established prostate and breast cancer cell lines we sequenced the HLA-A and HLA-B loci of eight commonly used cell lines and analyzed their HLA-ABC cell surface expression. We found that LNCaP, PC-346C, and MCF-7 are HLA-A*0201 positive. However, the HLA-A2 protein expression level is low and among the three cell lines only MCF-7 upregulates HLA-A2 expression in response to IFN-g stimulation. peptide epitopes may be too low for efficient CTL lysis. On the other hand, our data indicate that MCF-7 could, in many cases, be used as a complement to HLA-A*0201 positive prostate cancer target cells for in vitro T cell analysis. The drawback with MCF-7 is that it does not express all relevant prostate TAAs.
It has recently been shown that interaction between lymphocyte function-associated antigen-1 (LFA-1) on the CTL and CD54 (ICAM-1) on the target cell leads to a larger contact and a unique positioning of granules near the interface. This interaction directs the release of cytolytic granules to the surface of the antigen-expressing target cell and it mediates effective destruction of these cells by CTLs [16] . The fact that LNCaP and PC-346C express low levels of CD54 may render them poor target cells for CTL lysis. On the other hand DU145, BPH-1, PNT2-C2, MCF-7, and T47D express high levels of CD54 that would improve their value as target cells.
Despite the identification of TAAs and their immunogenic peptide epitopes for use as cancer vaccines, there is a steady interest in developing allogeneic (MHC-disparate) cancer vaccines by using tumor cell lines [17, 18] . For example, irradiated LNCaP and OnyCap23, a subclone of PNT2-C2, have been used as allogeneic prostate cancer vaccines [19] . However, the low expression levels of HLA-DR and costimulatory molecules (CD40, CD80, CD86) indicate that they are not optimal as antigen presenting cells for T cell activation. Therefore, to be efficient such therapeutic cancer vaccines would need to be targeted to professional antigen presenting cells such as dendritic cells. In addition, total RNA from LNCaP has recently been used as a source of prostate-related antigens in a phase I clinical trial [20] . Due to the wide expression of prostate-related antigens most prostate cancer cell lines analyzed in this article may be good sources of antigens for vaccination studies if combined with dendritic cells.
